Global Pneumococcal Vaccine Market 2016-2020 - Product Image

Global Pneumococcal Vaccine Market 2016-2020

  • ID: 3802104
  • Report
  • Region: Global
  • 82 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abera
  • Biken
  • Eli Lilly
  • GSK
  • Merck
  • Pfizer
  • MORE
About Pneumococcus

Pneumococcus (Streptococcus pneumoniae), a pathogenic bacterium, is the leading cause of serious illness worldwide. It is the major cause of pneumonia, blood infections, meningitis, sinusitis, and middle ear infections (otitis media). Pneumococcal infections affect children younger than five years and older people (65 years and older), and it is among the leading infectious disease. It kills almost 1.6 million people (including over 800,000 children under five years) every year. It can be prevented by vaccination and involves the introduction of a dead or weakened antigen into the human body. This produces lymphocytes to counter the infection and any future invasions by that antigen.

The analysts forecast the global pneumococcal vaccine market to grow at a CAGR of 13.69% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global pneumococcal vaccine market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of vaccines used to prevent pneumococcal infections.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Pneumococcal Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- GlaxoSmithKline (GSK)
- Merck
- Pfizer
- Sanofi

Other prominent vendors
- Abera
- AstraZeneca
- Baxter
- Beijing Minhai Biotechnology
- Biken
- Biogen
- Celgene
- Eli Lilly
- Genentech
- Genocea Biosciences
- ImmunoBiology
- Lupin
- Nuron Biotech
- Panacea Biotec (India)
- S K Chemicals
- Serum Institute of India
- Sinovac
- Valneva Austria

Market drivers
- Inclusion in NIP
- For a full, detailed list, view the full report

Market challenges
- Inadequate vaccine coverage
- For a full, detailed list, view the full report

Market trends
- Expansion of marketing territories
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abera
  • Biken
  • Eli Lilly
  • GSK
  • Merck
  • Pfizer
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Pneumococcal vaccine: Overview
  • Vaccine approval process
PART 06: Market landscape
  • Market overview
  • Five forces analysis
  • Market segmentation by composition
  • Global PCV market
  • Market overview
  • Global PPV market
  • Market overview
PART 07: Geographical segmentation
  • Pneumococcal vaccine market in Americas
  • Pneumococcal vaccine market in EMEA
  • Pneumococcal vaccines market in APAC
PART 08: Market drivers
  • Inclusion in NIP
  • Broad serotype coverage
  • Global action plans for pneumonia vaccines
PART 09: Impact of drivers

PART 10: Market challenges
  • Inadequate vaccine coverage
  • Require cold storage
  • High risk and cost involved in vaccine development
  • Stringent regulatory guidelines
PART 11: Impact of drivers and challenges

PART 12: Market trends
  • Expansion of marketing territories
  • Emergence of protein-based combination pneumococcal vaccines
  • AMC for pneumococcal vaccines
  • Bio-terrorism
  • Public–private initiatives
PART 13: Vendor landscape
  • Competitive scenario
  • Key news
  • Pfizer
  • Sanofi
  • GSK
  • Merck
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
PART 15: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Market share of pneumococcus vaccine market in global pharmaceutical market 2015
Exhibit 03: Market share of pneumococcal vaccine markets in global pharmaceutical market, 2015
Exhibit 04: Global pneumococcal vaccine market snapshot
Exhibit 05: Milestones in pneumococcus vaccines development
Exhibit 06: Key buying criteria for pneumococcal vaccine 2015
Exhibit 07: Impact of key customer segments on market 2015
Exhibit 08: Requirements for a BLA submission
Exhibit 09: Types of development necessary to reach vaccine licensing stage
Exhibit 10: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion
Exhibit 11: Regulatory testing of licensed vaccines
Exhibit 12: Economic burden of pneumococcal disease in children 2015
Exhibit 13: Total global costs for treating pneumococcal disease 2015 ($ billions)
Exhibit 14: Global pneumococcal vaccine market snapshot: Developed and emerging markets 2015
Exhibit 15: Overview of vaccine-related acquisitions 2005-2012
Exhibit 16: Global pneumococcal vaccine market 2015-2020 ($ billions)
Exhibit 17: Approved pneumococcal serotypes
Exhibit 18: Global pneumococcal vaccines market by volume 2013-2020 (million doses)
Exhibit 19: Impact of drivers and challenges on global pneumococcal vaccine market
Exhibit 20: Five forces analysis
Exhibit 21: Global pneumococcal vaccines market: Segmentation by composition 2015-2020
Exhibit 22: Global pneumococcal vaccines market segmentation by application 2015
Exhibit 23: Global pneumococcal vaccines market segmentation: Growth cycle analysis
Exhibit 24: Global supply and demand of PCV ($ millions) (2010-2017)
Exhibit 25: Price evolution of PCV (2009-2015)
Exhibit 26: Global PCV market 2015-2020 ($ billions)
Exhibit 27: Opportunity analysis of global conjugate vaccines market by composition
Exhibit 28: Global PPV market 2015-2020 ($ billions)
Exhibit 29: Opportunity analysis of global polysaccharide vaccines market by composition
Exhibit 30: Global PPV market segmentation by composition 2015
Exhibit 31: Global pneumococcal vaccine market by geography 2015
Exhibit 32: Global pneumococcal vaccine market: Geographical outlook (2015-2020)
Exhibit 33: Global pneumococcal vaccine market: Geographical outlook 2015
Exhibit 34: Segmentation of global pneumococcal vaccine market by region: Market growth lifecycle analysis 2015
Exhibit 35: Opportunity analysis of pneumococcal vaccine market in Americas
Exhibit 36: Pneumococcal vaccine market in Americas 2015-2020 ($ billions)
Exhibit 37: Pneumococcal vaccine market in Americas: PEST analysis
Exhibit 38: Opportunity analysis of pneumococcal vaccine market in EMEA
Exhibit 39: Pneumococcal vaccine market in EMEA 2015-2020 ($ billions)
Exhibit 40: Pneumococcal vaccine market in EMEA: PEST analysis
Exhibit 41: Opportunity analysis of pneumococcal vaccine market in APAC
Exhibit 42: Pneumococcal vaccine market in APAC 2015-2020 ($ billions)
Exhibit 43: Pneumococcal vaccine market in APAC: PEST analysis
Exhibit 44: Impact of drivers
Exhibit 45: A typical cold chain process
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Global pneumococcal vaccines market: Impact assessment of key trends 2015
Exhibit 48: Developing countries and their approval status for GAVI support
Exhibit 49: Pneumococcal procurement volumes through AMC (million doses)
Exhibit 50: Geographical presence of top vendors in global pneumococcal vaccine market 2015
Exhibit 51: Competitive assessment of vendors
Exhibit 52: Key vendors: Geographical presence 2015
Exhibit 53: Pfizer: YoY revenue and growth rate of Prevnar 2013-2015 ($ billions)
Exhibit 54: Pfizer: Revenue forecast of Prevnar 2016-2020 ($ billions)
Exhibit 55: Pfizer: Metrics analysis
Exhibit 56: Sanofi: YoY revenue growth of Meningitis/pneumonia vaccines 2013-2015 ($ millions)
Exhibit 57: Geographical segmentation of meningitis vaccines/PCVs by revenue 2015
Exhibit 58: Sanofi: Metrics analysis
Exhibit 59: GSK: YoY revenue and growth rate of Synflorix 2013-2015 ($ millions)
Exhibit 60: GSK: YoY geographical revenue of Synflorix 2013-2015 ($ millions)
Exhibit 61: GSK: Geographical segmentation of Synflorix 2015
Exhibit 62: Synflorix price per dose in different countries
Exhibit 63: GSK: Metrics analysis
Exhibit 64: Merck: YoY revenue growth of Pneumovax 23 2013-2015 ($ millions)
Exhibit 65: Merck: Metrics analysis
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abera
  • Biken
  • Eli Lilly
  • GSK
  • Merck
  • Pfizer
  • MORE
New Report Released: – Global Pneumococcal Vaccine Market 2016-2020

The author of the report recognizes the following companies as the key players in the global pneumococcal vaccine market: Pfizer, Sanofi, Merck, and GSK.

Other Prominent Vendors in the market are: Abera, AstraZeneca, Baxter, Beijing Minhai Biotechnology, Biken, Biogen, Celgene, Eli Lilly, Genentech, Genocea Biosciences, ImmunoBiology, Lupin, Nuron Biotech, Panacea Biotec, S K Chemicals, Serum Institute of India, Sinovac, and Valneva Austria.

Commenting on the report, an analyst from the research team said: “Emergence of protein-based combination pneumococcal vaccines will be a key trend for market growth. There is an increasing number of new pneumococcal protein-based vaccines, which are undergoing clinical trial evaluations. These protein-based vaccines consist of serotype-independent subunit vaccines containing purified proteins and antigens that are expressed by recombinant bacteria. These vaccines will avoid the problems of serotype replacement by directly targeting proteins that are highly preserved among many pneumococcal serotypes.”

According to the report, availability of global action plans for pneumonia vaccines will be a key driver for market growth. A consultation was held in Geneva in 2006, where WHO, in collaboration with vaccine manufacturers, public health organizations, academic experts, and funding agencies from developed and developing countries, developed the global action plan for pneumococcal vaccine. The plan was intended to combat the global shortage of pneumococcal vaccine. It is a comprehensive strategy focused on increasing the use of the vaccine, and increasing its production capacity and R&D. WHO is working to promote the use of pneumonia vaccines by encouraging its member states to develop a policy for pneumonia vaccination.

Further, the report states that inadequate vaccine coverage will be a challenge for the market. The coverage rates for a vaccine indicate the level of acceptance and extent of immunization for that vaccine. Negligence and lack of awareness among individuals, despite the subsidies offered by the government, is a major factor decreasing these coverage rates. Studies have estimated that the total global PCV coverage was at 19% in 2014. Studies also say that the coverage was 20% among the adults aged 19-64 years in 2013 in the US. The vaccination rate was higher in the adults aged 65 years and above, which was reported at 59.9%. The overall rate for pneumococcus infection was around 17% among vaccine-eligible subjects.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Pfizer
- Sanofi
- Merck
- GSK
- Abera
- AstraZeneca
- Baxter
- Beijing Minhai Biotechnology
- Biken
- Biogen
- Celgene
- Eli Lilly
- Genentech
- Genocea Biosciences
- ImmunoBiology
- Lupin
- Nuron Biotech
- Panacea Biotec
- S K Chemicals
- Serum Institute of India
- Sinovac
- Valneva Austria
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll